Clinical Trials Arena on MSN3d
Lundbeck’s superagonist prompts 61.2% seizure reduction
Results from the open-label extension portion of the Pacific trial saw bexicaserin able to elicit seizure reduction in ...
Pharmaceutical Technology on MSN4d
Neurona raises $102m to advance cell therapy for drug-resistant epilepsy
Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant ...
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline
The oversubscribed private financing round, with primary participation from Fidelity Management & Research Company, The Column Group, ...
Fierce Biotech4d
Cell therapy biotech Neurona nabs $102M to push epilepsy candidate into phase 3
Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.